Merz Aesthetics Celebrates A New Milestone: Ten Million Syringes of Radiesse® Shipped Worldwide
20.10.2020 13:36:00 EEST | Business Wire | Press release
Merz Aesthetics, a global leader in medical aesthetics, today announced that Radiesse® is celebrating ten million syringes shipped worldwide over almost twenty years. Radiesse® is a unique calcium hydroxylapatite (CaHA) injectable filler1 used for volumization, lifting and contouring, as well as skin rejuvenation by stimulating natural collagenogenesis.2,3 The product portfolio includes Radiesse® and Radiesse® Lidocaine delivering effective and natural-looking cosmetic results, distinguished by its established safety profile4 and high patient satisfaction.5
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005619/en/
Radiesse History (Graphic: Business Wire)
“As we reflect on this milestone, we are proud of the fact that, Radiesse has proven to provide aesthetic practitioners with a unique treatment that they can administer confidently, while supporting their patients’ desired impact,” said Kristel Hectors, Head of Marketing EMEA, Merz Aesthetics. “With almost twenty years of scientific evidence and clinical experience, Radiesse is such a unique product and full of opportunities and possibilities. As we are looking ahead, we are excited for what’s to come over the next years for Radiesse.”
The milestone campaign launching under the tagline “The Power Used By Millions” reinforces the uniqueness of the product and its working mechanism. Informing health care professionals and educating patients on the uniqueness of Radiesse®, on its working mechanism and efficacy.
“Radiesse is my number one go to product because of its versatility. Radiesse plus for contouring, lifting, ligaments and volumizing. Classic Radiesse for classic indications like folds and of course hyperdiluted Radiesse for skin quality improvement,” said Jani van Loghem, MD Cosmetisch arts KNMG. “It is a biostimulatory product going beyond a hyaluronic acid: the collagen will be giving the patient the final result and it is a really nice message to the patient! That’s why I choose Radiesse.”
About Radiesse®/Radiesse® (+) Lidocaine
Radiesse® is an injectable dermal filler that provides immediate volume and correction and continues to work by stimulating the body’s own natural collagen production. In addition, Radiesse activated the self-renewing potential within the skin to make the skin firm, elastic and strong. Radiesse can be tailored to individual requirements and skin condition.1,6-10
Radiesse® (+) Lidocaine injectable implant is an opaque, dermal filler that contains a small quantity of local anesthetic (lidocaine). In Europe, Radiesse® (+) Lidocaine is indicated for plastic / reconstructive procedures, including deep dermal and subdermal soft tissue augmentation of the facial area and for restoration and correction of facial volume loss. The presence of lidocaine is intended to reduce patient pain and to enhance comfort during treatment.1,6-10
Radiesse® / Radiesse® (+) Lidocaine is valued by doctors and patients around the world for its tolerability and safety profile. Radiesse received the CE mark for aesthetic use in Europe in 2004, with U.S. FDA approval following in 2006. In that time, Radiesse has been considered a leading minimally-invasive aesthetic treatment trusted by healthcare providers around the world. The product has been available on the market for more than fifteen years, with now 10 million syringes shipped worldwide and a clinically proven safety profile supported by more than 200 clinical studies and peer-reviewed publications.1,6-10
Radiesse is available in more than 70 countries worldwide.
About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. Radiesse® is a registered trademark of Merz North America, Inc.
1 RADIESSE Instructions for Use Nov. 2017. RADIESSE® Lidocaine Instructions for Use Jun.2018.
2 Berlin AL, et al. Dermatol Surg. 2008;34(suppl 1):S64-S67.
3 Moers-Carpi M, et al. Dermatol Surg. 2007;33(suppl 2):S144-S151.
4 Van Loghem JV, et al. J Clin Aesthet Dermatol. 2015:8(1)38-49.
5 Juhász MLW, Marmur ES, Dermatol Surg. 2018;44(8)1084-93.
6 Yutskovskaya Y, et al. J Drugs Dermatol. 2014;13(9):1047-52.
7 Yutskovskaya YA, Kogan EA. J Drugs Dermatol. 2017;16(1):68-74.
8 Schachter D, et al. J Drugs Dermatol. 2016 Aug 1; 15(8): 1005-10.
9 Sundaram H, et al. Dermatol Surg. 2010;36 (suppl 3):1859-1865.
10 Schachter Science Brief: Pain Control using the Injectable Dermal Filler Radiesse (+) for the correction of Nasolabial folds. Daniel Schachter, Vince Bertucci, Nowell Solish. POSTER PRESENTATION at 13th Anti-Aging Medicine World Congress (2015), Monaco, Monte Carlo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005619/en/
Contact information
Media Contact
Merz Pharmaceuticals GmbH
Regional Communications EMEA
Felicia Glatzel
Email: felicia.glatzel@merz.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 14:00:00 EEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performance, reliability and trusted supply chains. Its drones support national security and public-safety operations, sear
Enhertu ® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 14:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DESTI
SLB Announces Second-Quarter 2026 Results24.7.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8,721 $8,546 3% 5% Income before taxes - GAAP basis $1,018 $956 $1,285 6% -21% Income before taxes margin - GAAP basis 11.3% 11.0% 15.0% 38 bps -369 bps Net income attributable to SLB - GAAP basis $786 $752 $1,014 5% -22% Diluted EPS - GAAP basis $0.52 $0.50 $0.74 4% -30% Adjusted EBITDA* $1,899 $1,773 $2,051 7% -7% Adjusted EBITDA margin* 21.2% 20.3% 24.0% 83 bps -284 bps Pretax segment operating income* $1,404 $1,321 $1,584 6% -11% Pretax segment operating margin* 15.6% 15.2% 18.5% 49 bps -289 bps Net income attributable to SLB, excluding charges & credits* $833 $783 $1,0
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 13:30:00 EEST | Press release
NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps businesses realize the full value of NIQ's trusted market intelligence by automatically surfacing the trends, opportunities and
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 11:05:00 EEST | Press release
In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-government agreement, funded under the European Union’s SAFE programme, underlines the high level of partnership between France and Romania. The first delivery is expected in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260724603527/en/ The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200MM/A) radars to protect the Romanian airspace. The GM200 MM/A is a combat-proven medium-range 4D AESA radar, already deployed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom